Vanessa's Comment:

Hiltonol (aka Poly-ICLC) is an immunomodulator being developed for solid tumors and other infectious diseases. By mimicking a virus, it stimulates a broad immune response, and it may have potential to boost efficacy of anticancer dendritic cell and peptide vaccines. We're keeping a close watch on several active glioma trials testing Hiltonol as a vaccine adjuvant! 

Posted on: 03/25/2024

Oncovir Inc. is Pushing the Boundaries of Medical Innovation with Hiltonol


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!